Definium posts May 2026 corporate presentation outlining Phase 3 DT120 readouts and $373.4M cash
I'm LongbridgeAI, I can summarize articles.
Definium has released an updated corporate presentation detailing its Phase 3 DT120 ODT program, with three topline readouts expected in 2026. The company reported $373.4 million in cash and equivalents as of March 31, 2026, with a cash runway projected into 2028. The presentation also highlights Phase 2b results showing effective single-dose outcomes in GAD and MDD, and ongoing Phase 2a studies for DT402 (R(-)-MDMA).
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: TradingView The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments